Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
Status:
Completed
Trial end date:
2017-01-05
Target enrollment:
Participant gender:
Summary
Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin
in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in
combination with cisplatin, to characterize the safety profile, the pharmacokinetics (PK) of
this combination, to obtain preliminary information on the clinical antitumor activity and to
conduct an exploratory pharmacogenomic (PGx) analysis.